The head of US mergers and acquisitions at UBS is championing his optimism this year for mergers and acquisitions, reports say.
Marc-Anthony Hourihan offered an interview in which the executive sees positive growth from M&A deals throughout the globe thanks to a more stable economy in Europe and boosted investment activity.
Hourihan said he considers last year’s merger results to be “fairly good,” but the uncertainty within the EU economy hampered growing results. Further, the expert sees “real estate, technology and healthcare” will likely be the industries that see major acquisition deals in 2014.
Hourihan has been with UBS for two decades and has advised on major deals including the $6.5 billion buyout of ImClone Systems by Eli Lilly.
Full Content: MarketWatch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI